Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) approved EBGLYSSâ„¢ (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults and ...
Some results have been hidden because they may be inaccessible to you